Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 7

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 7
---
 Selling Shareholder’s obligation to purchase Common Shares set forth in the Purchase Agreement (the “Commencement”),
including a registration statement registering the resale by the Investor of the Common Shares under the Securities Act that may be sold
to it by us under the Purchase Agreement, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC,
we will have the right, but not the obligation, from time-to-time to its sole discretion until the first day of the month next following
the 36-month period from and after Commencement, to direct the Investor to purchase up to a specified maximum amount of Common Shares
as set forth in the Purchase Agreement by delivering written notice to the Investor prior to the commencement of trading on any trading
day. The purchase price of the Common Shares that we elect to sell to the Selling Shareholder pursuant to the Purchase Agreement will
be 95% of the volume weighted average price of the Common Shares during the applicable purchase date on which we have timely delivered
written notice to the Selling Shareholder directing it to purchase Common Shares under the Purchase Agreement (a “VWAP Purchase”).

In connection with the
Purchase Agreement, we also agreed to issue the Selling Shareholder the Commitment Shares, and as such we issued the Selling Shareholder
a pre-funded warrant to purchase 192,308 Common Shares as Commitment Shares. The Purchase Agreement contains customary registration rights,
representations, warranties, conditions and indemnification obligations by each party. The representations, warranties and covenants
contained in the Purchase Agreements were made only for purposes of the Purchase Agreements and as of specific dates, were solely for
the benefit of the parties to such agreements and are subject to certain important limitations.

We have the right to terminate the Purchase Agreement at any time after Commencement, at no cost or penalty, upon 10 days’ prior written notice. No termination of the Purchase Agreement will affect the registration rights provisions contained within the Purchase Agreement, which will survive any termination of the Purchase Agreement.

Agreement and Plan of Merger with Kadimastem

On November 4, 2024, the
Company, NLS Pharmaceutics (Israel) Ltd., an Israeli company and a wholly-owned subsidiary of the Company (the “Merger Sub”)
and Kadimastem Ltd. an Israeli publicly traded company limited by shares (TASE: KDST)(“Kadimastem”), entered into an Agreement
and Plan of Merger (the